Lilly paid $75 million upfront for a GLP-2 analog still in Phase 2 for short bowel syndrome — a rare disease with a market measured in tens of thousands of patients globally. That apparent mismatch is the whole point. The $1.26 billion deal ceiling signals Lilly is not buying a short bowel syndrome drug; it is buying optionality across a far broader intestinal biology franchise, and it is paying Korean biotech prices to do it before the indication map gets written.
Sonefpeglutide’s mechanism is worth unpacking. GLP-2 promotes intestinal mucosal growth, suppresses gut inflammation, and supports epithelial regeneration — functions with obvious relevance beyond SBS. Inflammatory bowel disease, radiation enteritis, chemotherapy-induced mucositis, and gut-barrier dysfunction in metabolic disease are all plausible expansion territories. Lilly inherits the existing Phase 2 SBS trial, which Hanmi retains operational responsibility for through completion, while Lilly runs parallel nonclinical and clinical work on additional indications. That split-responsibility structure is deliberate: Lilly gets the data without absorbing the near-term execution risk on a trial already in motion.
The strategic fit with Lilly’s existing portfolio is not subtle. Lilly already commands the GLP-1 space with tirzepatide and is aggressively building around metabolic and gastrointestinal biology. A long-acting GLP-2 analog extends that axis into intestinal repair rather than appetite suppression or glycemic control — complementary rather than cannibalistic. Hanmi’s LAPSCOVERY platform, which has already cleared FDA approval for one biologic, reduces the manufacturing credibility risk that often shadows Korean biotech assets at this stage. Lilly is not adopting an unproven platform; it is licensing validated half-life extension technology paired with a mechanism it does not currently own.
The one number that will determine whether this deal generates anywhere near its milestone ceiling is enrollment velocity in the ongoing SBS Phase 2. SBS is an orphan-scale indication, and Phase 2 readout timing directly controls when Lilly can file an IND for the next indication and begin stacking the clinical evidence needed to unlock the larger regulatory and commercialization milestones. Watch the SBS trial completion date — it is the single gating event for everything that follows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
